Mufg Securities Americas Inc. Grows Position in Gilead Sciences, Inc. $GILD

Mufg Securities Americas Inc. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 25.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,569 shares of the biopharmaceutical company’s stock after purchasing an additional 5,509 shares during the period. Mufg Securities Americas Inc.’s holdings in Gilead Sciences were worth $3,057,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Activest Wealth Management boosted its holdings in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $27,000. Putney Financial Group LLC increased its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares in the last quarter. Finally, Colonial Trust Advisors increased its stake in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This trade represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 125,146 shares of company stock valued at $15,148,441. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 1.3%

Shares of NASDAQ GILD opened at $126.64 on Friday. The firm has a market cap of $157.12 billion, a P/E ratio of 25.23, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The firm’s 50 day moving average price is $118.48 and its 200 day moving average price is $113.54.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is 48.99%.

Analyst Ratings Changes

Several analysts have weighed in on the company. Scotiabank assumed coverage on Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price on the stock. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Daiwa Capital Markets raised their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Citigroup upped their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Finally, Argus increased their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.45.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.